相关实验视频

Updated: Jun 29, 2025

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

拉巴胺素与TORin-1或Gleevec与尼洛丁尼:简单的化学进化,将PAK1阻断剂转化为TOR阻断剂或反之?

Hiroshi Maruta¹, Hong He²

¹PAK Research Center, Melbourne, Australia.

Drug discoveries & therapeutics

|April 3, 2024

概括

PAK1 (RAC/CDC42-激活激酶1) 和TOR (拉巴胺的标) 激酶在免疫中具有相反的作用. 与TOR阻断剂不同的是,PAK1阻断剂通过抑制黑色素生成,对癌症治疗和长寿有希望.

科学领域:

生物化学生物化学
在瘤学瘤学.
免疫学免疫学免疫学
衰老研究研究衰老研究

背景情况:

PAK1 (RAC/CDC42-激活酶1) 和TOR (拉巴胺的标) 是关键酶,它们与癌症和衰老有关.
这些激酶在免疫系统调节中起着截然不同的作用:PAK1抑制免疫力,而TOR对其功能至关重要.

研究的目的:

研究PAK1和TOR在免疫功能和癌症中的不同作用.
确定针对这些激酶的有效治疗策略,以治疗癌症和延长寿命.
探索黑色素生成作为区分PAK1阻断剂和TOR阻断剂的潜在指标.

主要方法:

选PAK1阻断剂作为黑色素生成抑制剂.
在细胞培养模型中使用拉巴胺素 (TOR抑制剂) 和TORin-1 (新型TOR抑制剂).
评估这些抑制剂对免疫系统功能和黑色素的产生影响.

主要成果:

发现PAK1抑制可以抑制黑色素生成,并可能促进长寿.
拉帕米辛是一种TOR抑制剂,促进了黑色素的产生,这表明TOR抑制了这一过程.
虽然TORin-1被归类为TOR抑制剂,但它通过不抑制免疫系统和阻断体外黑色素生成而表现出类似PAK1抑制剂的作用.

结论:

由于它们的免疫作用相反,PAK1抑制剂在癌症治疗中可能比TOR抑制剂更有效.
细胞培养中的黑色素生成可以作为一种可靠的方法,以在体内区分PAK1抑制剂和TOR抑制剂.
观察到的TORin-1的效果表明,它可能在体内作为PAK1阻断剂发挥作用,提供了一种新的治疗途径.

关键词:

格利维克 (Gleevec) 是一个名字.这就是PAK1的原因.这就是TOR Tor.在TORin-1中使用.免疫系统免疫系统黑色素的产生是黑色素的产生.尼罗丁尼博丁是什么尼罗丁尼博丁这种药物是拉帕米辛 (Rapamycin).

更多相关视频

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases

Published on: September 6, 2024

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Drug Biotransformation: Overview

Drug Biotransformation: Overview

Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

Amplifying Signals via Enzymatic Cascade

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...